Schering-Plough sues Krka over patent
US pharmaceutical major Schering-Plough has filed a 1.0 million-euro ($1.3 million) law suit against the German subsidiary of Slovene drug producer Krka, Krka Aussenhandels. S-P claims Krka has infringed its patent rights by selling the drug Floron (florfenicol) - used extensively in veterinary medicine - in Germany.
Krka has denied the accusation, claiming that it has not sold the drug in Germany. "Krka and its subsidiary in Germany, Krka Aussenhandels GmbH, in Munich, Germany, did not and is not offering this product or active ingredient in Germany," the firm said in a statement.
The generic chemotherapeutical antibiotic Floron is used extensively in veterinary medicine and, apart from Enroxil (enrofloxacin), is Krka's best-selling veterinary drug. The company sold 20.0 million euros of veterinary products in 2005 - around 4% of total sales. Krka, founded in 1954, is Slovenia's largest pharmaceutical company, employing 4,700 workers and operating in 70 countries around the world, with an annual turnover of 484.0 million euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze